Switzerland
Switzerland, renowned for its precision, quality, and innovation, mirrors the ethos of Ka Pharmaceuticals. With our Swiss foundation, we are committed to advancing healthcare by bridging scientific innovation with accessibility. Ka Pharmaceuticals empowers patients, doctors, and pharmacists by delivering affordable, high-quality cannabinoid-based therapies. Through evidence-based education, stringent compliance with international standards, and innovative solutions, we aim to enhance patient outcomes and redefine healthcare globally. Together, we can shape a future where integrative, trusted therapies are a cornerstone of modern medicine.
Legal Status Switzerland
Doctor Prescriptions and Pharmacist Involvement
As of August 1, 2022, physicians in Switzerland are empowered to directly prescribe medical cannabis, free from the prior approval of the Federal Office of Public Health (FOPH).
These prescriptions are crafted using a standard narcotics prescription form, akin to those for other controlled substances.
Pharmacists assume a pivotal role in dispensing these prescriptions, ensuring adherence to Swissmedic regulations. They must confirm the correct formulation, dosage, and provide appropriate patient counsel.
Additionally, pharmacists are tasked with verifying the legality and authenticity of prescriptions, managing inventory in accordance with narcotics regulations, and reporting any misuse or irregularities.
Approved Medical Cannabis Products
The array of approved medical cannabis products in Switzerland encompasses cannabis oils and tinctures for oral or sublingual application, dried cannabis flowers for vaporization or other prescribed methods of consumption.
Pharmacies are authorized to dispense these products, ensuring product traceability.
Should a prescription be issued, pharmacists can also prepare custom formulations (e.g., oils with specific cannabinoid ratios), adhering to rigorous compounding guidelines.
Insurance Coverage and Patient Costs
Medical cannabis treatments do not automatically fall under Switzerland’s mandatory health insurance (LaMal). In exceptional circumstances, patients may seek reimbursement, particularly for severe or chronic conditions that have proven resistant to standard therapies.
When insurance coverage is absent, patients shoulder the entire cost of medical cannabis, which can vary significantly based on the product and dosage.
Pharmacists are responsible for enlightening patients about cost implications and may assist in compiling documentation for reimbursement requests when applicable.
References
Our Certifications
